• LAST PRICE
    1.9500
  • TODAY'S CHANGE (%)
    Trending Down-0.0488 (-2.4415%)
  • Bid / Lots
    1.8200/ 5
  • Ask / Lots
    0.0000/ 0
  • Open / Previous Close
    2.0000 / 1.9988
  • Day Range
    Low 1.8900
    High 2.2499
  • 52 Week Range
    Low 1.8100
    High 6.0000
  • Volume
    37,108
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 1.9988
TimeVolumeCHRO
09:32 ET8002
09:34 ET11142.04
09:36 ET6412.1
09:38 ET11762.19
09:39 ET13002.17
09:41 ET5002.16
09:43 ET25792.01
09:45 ET11002
09:48 ET23122.15
09:50 ET14992
09:52 ET25002.13
09:54 ET10002.11
09:57 ET2002.05
09:59 ET3562
12:18 ET5002.0599
02:18 ET1002.01
02:31 ET44571.96
02:51 ET1501.95
02:58 ET1001.95
03:02 ET1001.9512
03:20 ET5701.945
03:21 ET10961.93
03:23 ET3931.93
03:36 ET16261.91
03:38 ET4001.91
03:39 ET1001.95
03:41 ET20001.93
03:43 ET5991.95
03:59 ET01.95
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCHRO
Chromocell Therapeutics Corp
11.5M
-2.8x
---
United StatesASLN
Aslan Pharmaceuticals Ltd
11.7M
-0.2x
---
United StatesGCTK
GlucoTrack Inc
11.2M
-1.2x
---
United StatesCMMB
Chemomab Therapeutics Ltd
10.9M
0.0x
---
United StatesABVC
ABVC Biopharma Inc
11.5M
-0.4x
---
United StatesERNA
Eterna Therapeutics Inc
12.1M
-0.5x
---
As of 2024-04-15

Company Information

Chromocell Therapeutics Corporation is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. The Company's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.

Contact Information

Headquarters
685 Us Highway OneNORTH BRUNSWICK, NJ, United States 08902
Phone
917-644-6313
Fax
302-658-3694

Executives

Chairman of the Board
Todd Davis
Chief Executive Officer, Chief Financial Officer, Treasurer, Company Secretary
Francis Knuettel
Chief Medical Officer
Eric Lang
Independent Director
Ezra Friedberg
Independent Director
Richard Malamut

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$11.5M
Revenue (TTM)
$0.00
Shares Outstanding
5.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.71
Book Value
$-0.64
P/E Ratio
-2.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.